Table 2 Treatment-related adverse events that occurred in ≥ 5% of patients (n = 1999)
Treatment-related adverse events, n (%) | All Grade | Grade ≥ 3 |
|---|---|---|
Any event | 1757 (88%) | 1019 (51%) |
Serious adverse event | 259 (13%) | 203 (10%) |
Hypertension | 903 (45%) | 490 (25%) |
Proteinuria | 530 (27%) | 77 (4%) |
White blood cell count decreased | 506 (25%) | 35 (2%) |
Fatigue | 438 (22%) | 41 (2%) |
Platelet count decreased | 417 (21%) | 73 (4%) |
Neutrophil count decreased | 363 (18%) | 54 (3%) |
hand-foot syndrome | 330 (17%) | 62 (3%) |
Positive fecal occult blood test | 288 (14%) | 11 (1%) |
Decreased appetite | 250 (13%) | 22 (1%) |
Diarrhea | 247 (12%) | 25 (1%) |
Aspartate aminotransferase increased | 247 (12%) | 26 (1%) |
Anemia | 243 (12%) | 56 (3%) |
Emesis | 225 (11%) | 22 (1%) |
Blood bilirubin increased | 214 (11%) | 33 (2%) |
Nausea | 212 (11%) | 18 (1%) |
Alanine aminotransferase increased | 169 (8%) | 20 (1%) |
Urine protein present | 163 (8%) | 13 (1%) |
Hepatic function abnormal | 158 (8%) | 39 (2%) |
Gamma-glutamyltransferase increased | 154 (8%) | 60 (3%) |
Abdominal pain | 138 (7%) | 24 (1%) |
Blood alkaline phosphatase increased | 134 (7%) | 28 (1%) |